Cargando…

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice

AIMS: In post‐menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits. We tested whether the non‐steroidal mineralocorticoid receptor antagonist finerenone limits the progression of heart failure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pieronne‐Deperrois, Marie, Guéret, Alexandre, Djerada, Zoubir, Crochemore, Clément, Harouki, Najah, Henry, Jean‐Paul, Dumesnil, Anaïs, Larchevêque, Marine, do Rego, Jean‐Claude, do Rego, Jean‐Luc, Nicol, Lionel, Richard, Vincent, Jaisser, Frédéric, Kolkhof, Peter, Mulder, Paul, Monteil, Christelle, Ouvrard‐Pascaud, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120350/ https://www.ncbi.nlm.nih.gov/pubmed/33742556 http://dx.doi.org/10.1002/ehf2.13219

Ejemplares similares

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models
por: Bonnard, Benjamin, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure
por: Harouki, Najah, et al.
Publicado: (2017)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Transient heart rate reduction improves acute decompensated heart failure‐induced left ventricular and coronary dysfunction
por: Peschanski, Nicolas, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition
por: Ibarrola, Jaime, et al.
Publicado: (2019)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
por: Jerome, Jack R., et al.
Publicado: (2023)

Regulation and impact of cardiac lymphangiogenesis in pressure-overload-induced heart failure
por: Heron, Coraline, et al.
Publicado: (2022)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone
por: Pollard, Celina M, et al.
Publicado: (2022)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

SAT-LB106 Metabolic and Brown Adipose Tissue-Specific Effects of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in a Mouse Model of Diet-Induced Obesity
por: Marzolla, Vincenzo, et al.
Publicado: (2020)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
por: Di Lullo, Luca, et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice
por: Figueroa, Stefanny M., et al.
Publicado: (2023)

Nitrogen Dioxide Inhalation Exposures Induce Cardiac Mitochondrial Reactive Oxygen Species Production, Impair Mitochondrial Function and Promote Coronary Endothelial Dysfunction
por: Karoui, Ahmed, et al.
Publicado: (2020)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis
por: Pei, Hui, et al.
Publicado: (2018)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

Immunoglobulin G is a natural oxytocin carrier which modulates oxytocin receptor signaling: relevance to aggressive behavior in humans
por: Værøy, Henning, et al.
Publicado: (2023)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
por: Yao, Lan, et al.
Publicado: (2023)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
por: González-Blázquez, Raquel, et al.
Publicado: (2018)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Priming of Cardiopulmonary Bypass with Human Albumin Decreases Endothelial Dysfunction after Pulmonary Ischemia–Reperfusion in an Animal Model
por: Selim, Jean, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8fo1tvh654b1miromtdl7fmk13